These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 1436302

  • 1. Treatment of hyperlipidemia in nephrotic syndrome: time for a change?
    Olbricht CJ, Koch KM.
    Nephron; 1992; 62(2):125-9. PubMed ID: 1436302
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U.
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rationale and management of hyperlipidemia of the nephrotic syndrome.
    Grundy SM, Vega GL.
    Am J Med; 1989 Nov; 87(5N):3N-11N. PubMed ID: 2486542
    [Abstract] [Full Text] [Related]

  • 7. [Hyperlipidemia in nephrotic syndrome].
    Heaf JG.
    Ugeskr Laeger; 1991 Aug 26; 153(35):2414-6. PubMed ID: 1949240
    [Abstract] [Full Text] [Related]

  • 8. [Recent trends in the therapy of hyperlipidemia in nephrotic syndrome].
    Campanacci L, Guarnieri GF, Faccini L, Bellini G, Gambari PF.
    G Clin Med; 1973 Oct 26; 54(10):714-33. PubMed ID: 4789301
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S.
    Nephron; 1987 Oct 26; 47(4):280-3. PubMed ID: 3696330
    [Abstract] [Full Text] [Related]

  • 11. Lipid-lowering agents in proteinuric diseases.
    Appel GB, Appel AS.
    Am J Nephrol; 1990 Oct 26; 10 Suppl 1():110-5. PubMed ID: 2256470
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Disturbances of lipid metabolism during nephrotic syndrome: physiopathology and treatment].
    Moulin B, Ollier J, Olmer M.
    Nephrologie; 1992 Oct 26; 13(5):193-9. PubMed ID: 1470293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Severe hyperlipidemia due to multiple factors in a child with nephrotic syndrome.
    Ongkingco JR, Mann WA, Ruley EJ, Gregg RE.
    Child Nephrol Urol; 1991 Oct 26; 11(2):107-10. PubMed ID: 1756519
    [Abstract] [Full Text] [Related]

  • 17. Dyslipidemia in pediatric nephrotic syndrome: causes revisited.
    Delvin EE, Merouani A, Levy E.
    Clin Biochem; 2003 Mar 26; 36(2):95-101. PubMed ID: 12633757
    [No Abstract] [Full Text] [Related]

  • 18. [Activity of the clearing factor in the pathogenesis of hyperlipidemia in experimental nephrotic syndrome].
    Nikiforova NV.
    Biull Eksp Biol Med; 1966 Dec 26; 62(12):29-32. PubMed ID: 6005418
    [No Abstract] [Full Text] [Related]

  • 19. Management of hyperlipidemia of kidney disease.
    Grundy SM.
    Kidney Int; 1990 Mar 26; 37(3):847-53. PubMed ID: 2179614
    [No Abstract] [Full Text] [Related]

  • 20. [Complications of nephrotic syndrome (NS) and the possibility of their treatment].
    Myśliwiec M.
    Przegl Lek; 1992 Mar 26; 49(1-2):23-5. PubMed ID: 1280841
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.